Psychedelic Investments Week in Review (28 March 2020)

Post published:March 28, 2020
Post category:News

We’re taking a look back at this week’s developments in the psychedelics market.

Champignon Brands ($SHRM)

We have two updates on Champignon this week.

On March 27th, 2020, Champignon entered into a definitive agreement to acquire Tassili Life Sciences, who work with various university research institutes to demonstrate the clinical and physiological efficacy of Psilocybin and CBD with regard to post-concussion syndrome, PTSD, and OCD.

Details of this all-share transaction can be found in the press release.

The second piece of news from Champignon is their appointment of Dr. Joseph Gabrielle to their special advisory committee.

Gabrielle is a molecular pharmacological who has received a variety of awards, including a number of “New Investigator Awards” and the Ernst & Young Entrepreneur of the Year in Healthcare title. More information is available in the press release.

MindMed ($MMED)

Earlier this week MindMed announced that it has opened enrolment in a new suite of safety studies for their non-hallucinogenic proprietary molecule: 18-MC. The substance has shown early promise in its potential for mitigating a number of forms of addiction. Read the full press release here.

That’s all for this week. We hope you’re staying safe during these unprecedented times.

If we missed anything, or you’d like to see us write about something, don’t hesitate to let us know.

Developing Esketamine (Spravato) and Lessons for Psychedelic Drug Developers with Jaskaran SinghApril 12, 2024
Josh Hardman sits down with Jaskaran (‘Jaz’) Singh, who spearheaded the development of esketamine for treatment-resistant depression, now marketed as Spravato. We discuss how Singh’s early work assessing ketamine’s antidepressant effects at the National Institute of Mental Health (NIMH) encouraged him to move into industry; how his team decided to pursue esketamine; lessons learned that might be relevant for psychedelic drug developers; and his broader outlook on the field.
Natural Medicine Advisory Bulletin 10.1: Legislative UpdateApril 9, 2024
Vicente LLP reviews Senate Bill 24-198, the first legislative since the passing of SB-23-290 in 2023, which implemented the Natural Medicine Health Act.
MindMed’s ‘Total Elimination’ of Psychotherapy in LSD Study Stokes Debate Around Its Role in Psychedelic TherapiesApril 5, 2024
In March, MindMed scored an FDA Breakthrough Therapy Designation for its LSD-D-tartrate candidate (MM120) for generalised anxiety disorder (GAD). Here, Josh takes a closer look at the company's claim to have ‘eliminated’ psychotherapy from its Phase 2b study of MM120 and explores how a ‘Spravato-isation’ of psychedelic therapies is stoking broader debates around the contribution of psychotherapy in psychedelic therapies or ‘treatments’.
Natural Medicine Advisory Bulletin 10: March 2024April 4, 2024
Vicente LLP reviews the March 15th Colorado Natural Medicine Advisory Board meeting, where draft rules for Facilitator licensing and training were discussed.
Senator Kirk Cullimore on Utah’s MDMA and Psilocybin Pilot ProgramApril 3, 2024
Josh Hardman speaks with the chief sponsor of Utah SB 266, which became law last month. The bill sees the creation of a pilot program that allows MDMA and psilocybin therapies to be administered at two health systems in the Beehive State. Questions remain, however, around the likelihood of these health systems engaging in such activity, as well as potential repercussions from federal agencies and professional bodies alike.